CYP3A7

Across TCGA pan-cancer cohorts, CYP3A7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP3A7 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CYP3A7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYP3A7 expression acts as an unfavorable survival marker.

HNSC, PRAD, and BLCA are the cancer types where CYP3A7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.208	0.695	.037	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	DFS	Median	IV	0.122	0.469	.022	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP3A7–HNSC (DFS)

Open the HNSC breakdown →